NASDAQ: CYCNCyclerion Therapeutics Inc Stock
$2.70-0.05 (-1.82%)
Updated Apr 21, 2025
CYCN Price
$2.70
Fair Value Price
$0.29
Market Cap
$7.32M
52 Week Low
$1.27
52 Week High
$9.47
P/E
-2.23x
P/B
0.83x
P/S
4.05x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.00M
Earnings
-$3.06M
Gross Margin
100%
Operating Margin
-152.85%
Profit Margin
-152.8%
Debt to Equity
0.08
Operating Cash Flow
-$4M
Beta
1.16
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CYCN Overview
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CYCN's potential to beat the market
- CYCN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CYCN
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important CYCN news, forecast changes, insider trades & much more!
CYCN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CYCN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CYCN ($2.70) is overvalued by 827.96% relative to our estimate of its Fair Value price of $0.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CYCN ($2.70) is not significantly undervalued (827.96%) relative to our estimate of its Fair Value price of $0.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CYCN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CYCN due diligence checks available for Premium users.
Valuation
CYCN fair value
Fair Value of CYCN stock based on Discounted Cash Flow (DCF)
Price
$2.70
Fair Value
$0.29
Overvalued by
827.96%
CYCN ($2.70) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CYCN ($2.70) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CYCN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CYCN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.23x
Industry
-184.27x
Market
27.14x
CYCN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.83x
Industry
4.04x
CYCN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CYCN's financial health
Profit margin
Revenue
$1.8M
Net Income
$530.0k
Profit Margin
29.3%
CYCN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CYCN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.6M
Liabilities
$725.0k
Debt to equity
0.08
CYCN's short-term assets ($4.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CYCN's short-term assets ($4.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CYCN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CYCN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$360.0k
Investing
$0.0
Financing
$0.0
CYCN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CYCN vs Biotech Stocks
Cyclerion Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.